Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635829 | 0.88 | LTA4H (0.44) | SLC6A4PPARGPPARALTA4HLMNA | |
| SCHEMBL7976811 | 0.86 | LTA4H (0.44) | SLC6A4LTA4HLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL11319699 | 0.85 | LTA4H (0.43) | SLC6A4LTA4HLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8554246 | 0.85 | LTA4H (0.43) | SLC6A4LTA4HLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL28177008 | 0.85 | LTA4H (0.43) | SLC6A4LTA4HLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2518650 | 0.85 | LTA4H (0.43) | SLC6A4LTA4HLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL10768358 | 0.83 | LTA4H (0.37) | SLC6A4PPARGPPARALTA4HLMNA | |
| Ammonia Solution, Strong SCHEMBL17311200 | 0.83 | LTA4H (0.42) | SLC6A4LTA4HLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9421467 | 0.83 | LMNA (0.52) | PPARGPPARALMNASMN1; SMN2 | |
| SCHEMBL25331886 | 0.83 | SLC6A4 (0.39) | SLC6A4PPARGPPARALTA4HMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115044244-A | Packaging ink composition with low curing shrinkage rate and preparation method thereof | 西安思摩威新材料有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3262026-B1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-18 | — | — | EP | disclosed |
| US-9980929-B2 | Trifluoromethylpropanamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3262026-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-01-03 | — | — | EP | disclosed |
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2016135070-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-01 | — | — | WO | disclosed |
| US-6043227-A | C11 carbamates of macrolide antibacterials | PFIZER INC. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0628026-A1 | CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE. | BASF AG (DE) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016985-A1 | CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-02 | — | — | WO | disclosed |
| US-4514401-A | CARDIOTONICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | PRMT7, GFRA3, PRMT5 | SLC6A4 1866/4885PPARG 3605/4885PPARA 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.